Evidence map›Paper›PMID 27662287›Full record

ArticleJournal of Alzheimer's disease : JAD2017

Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.

Burcu F Darst, Rebecca L Koscik, Annie M Racine, Jennifer M Oh, Rachel A Krause, Cynthia M Carlsson, Henrik Zetterberg, Kaj Blennow, Bradley T Christian, Barbara B Bendlin and 7 more

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 4 pooled it
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Language deficits across PET-based Braak stages of tau accumulation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Gut microbiome compositional and functional features associate with Alzheimer's disease pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  16. Article
  17. Physical activity andmedRxiv : the preprint server for health sciences · 2025
    Article
  18. Article
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Burcu F DarstUniversity of Wisconsin, Madison, WI, USA.
Rebecca L KoscikUniversity of Wisconsin, Madison, WI, USA.
Annie M RacineUniversity of Wisconsin, Madison, WI, USA.
Jennifer M OhUniversity of Wisconsin, Madison, WI, USA.
Rachel A KrauseUniversity of Wisconsin, Madison, WI, USA.
Cynthia M CarlssonUniversity of Wisconsin, Madison, WI, USA.
Henrik ZetterbergClinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sweden.
Kaj BlennowClinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sweden.
Bradley T ChristianUniversity of Wisconsin, Madison, WI, USA.
Barbara B BendlinUniversity of Wisconsin, Madison, WI, USA.
Ozioma C OkonkwoUniversity of Wisconsin, Madison, WI, USA.
Kirk J HoganUniversity of Wisconsin, Madison, WI, USA.
Bruce P HermannUniversity of Wisconsin, Madison, WI, USA.
Mark A SagerUniversity of Wisconsin, Madison, WI, USA.
Sanjay AsthanaUniversity of Wisconsin, Madison, WI, USA.
Sterling C JohnsonUniversity of Wisconsin, Madison, WI, USA.
Corinne D EngelmanUniversity of Wisconsin, Madison, WI, USA.
University of Wisconsin–Madison · USGeriatric Research Education and Clinical Center · USNational Hospital for Neurology and Neurosurgery · GBUniversity of Gothenburg · SEWilliam S. Middleton Memorial Veterans Hospital · US

Funding

Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
The Longitudinal Course of Neural Function and Amyloid in People At Risk for ADR01AG021155 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sterling C Johnson · 2004 to 2026
$27.0M
Research Training for Computation and Informatics in Biology and MedicineT15LM007359 · NLM · UNIVERSITY OF WISCONSIN-MADISON · PI Mark W. Craven, Colin Noel Dewey · 2002 to 2026
$22.6M
Statistical Data Enclave CoreP30AG017266 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Michal Engelman · 1999 to 2026
$17.0M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CHAPPELL, RICHARD J · 2009 to 2018
$16.2M
Biology of Aging and Age-Related Diseases Training GrantT32AG000213 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Rozalyn M. Anderson, Sanjay Asthana · 1991 to 2026
$9.9M
Center for Demography and EcologyR24HD047873 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI RAYMO, JAMES M · 2004 to 2013
$7.2M
Waisman Intellectual and Developmental Disabilities Research Center Down Syndrome RegistryU54HD090256 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI CHANG, QIANG · 2016 to 2020
$6.0M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
Scientific and Technical CoreP2CHD047873 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Katherine J. Curtis · 2014 to 2026
$5.1M
Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's DiseaseR01AG054047 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ENGELMAN, CORINNE D. · 2016 to 2020
$3.6M
NCATS NIH HHS UL1 TR000427NIA NIH HHS P30 AG017266NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG021155NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG054047NIA NIH HHS R56 AG037639NIA NIH HHS T32 AG000213NICHD NIH HHS P2C HD047873NICHD NIH HHS R24 HD047873NICHD NIH HHS U54 HD090256NLM NIH HHS T15 LM007359
6 · The paper itself

Abstract

Polygenic risk scores (PRSs) have been used to combine the effects of variants with small effects identified by genome-wide association studies. We explore the potential for using pathway-specific PRSs as predictors of early changes in Alzheimer's disease (AD)-related biomarkers and cognitive function. Participants were from the Wisconsin Registry for Alzheimer's Prevention, a longitudinal study of adults who were cognitively asymptomatic at enrollment and enriched for a parental history of AD. Using genes associated with AD in the International Genomics of Alzheimer's Project's meta-analysis, we identified clusters of genes that grouped into pathways involved in amyloid-β (Aβ) deposition and neurodegeneration: Aβ clearance, cholesterol metabolism, and immune response. Weighted pathway-specific and overall PRSs were developed and compared to APOE alone. Mixed models were used to assess whether each PRS was associated with cognition in 1,200 individuals, cerebral Aβ deposition measured using amyloid ligand (Pittsburgh compound B) positron emission imaging in 168 individuals, and cerebrospinal fluid Aβ deposition, neurodegeneration, and tau pathology in 111 individuals, with replication performed in an independent sample. We found that PRSs including APOE appeared to be driven by the inclusion of APOE, suggesting that the pathway-specific PRSs used here were not more predictive than an overall PRS or APOE alone. However, pathway-specific PRSs could prove to be useful as more knowledge is gained on the genetic variants involved in specific biological pathways of AD.

Indexed as

AdultAgedAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsApolipoproteins ECognition DisordersFemaleGenome-Wide Association StudyGenotypeHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsPolymorphism, Single Nucleotide2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsApolipoproteins Etau ProteinsThiazolesAlzheimer’s diseaseamyloid-betaAPOEcerebrospinal fluidcognitive functiongenetic risk scoresgeneticsPittsburgh compound Bpolygenic risk scoresWRAP

Identifiers

PMID27662287
PMCPMC5123972
OpenAlexW2462066030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.